Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. reduced its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 11.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,277 shares of the biopharmaceutical company’s stock after selling 668 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Ultragenyx Pharmaceutical were worth $222,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Smartleaf Asset Management LLC boosted its position in shares of Ultragenyx Pharmaceutical by 259.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 493 shares in the last quarter. True Wealth Design LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth about $43,000. Human Investing LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth about $42,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth about $83,000. Finally, Nomura Asset Management Co. Ltd. acquired a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth about $93,000. 97.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently issued reports on RARE. Canaccord Genuity Group upped their price objective on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th. Wedbush reissued a “neutral” rating and issued a $48.00 target price (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. HC Wainwright reissued a “buy” rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Wells Fargo & Company upped their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a research report on Friday, December 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $93.50.

Ultragenyx Pharmaceutical Stock Down 3.5 %

RARE opened at $38.62 on Monday. The business has a 50 day moving average price of $42.57 and a two-hundred day moving average price of $48.63. The company has a market cap of $3.57 billion, a PE ratio of -6.09 and a beta of 0.67. Ultragenyx Pharmaceutical Inc. has a 52 week low of $37.02 and a 52 week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). The business had revenue of $164.88 million for the quarter, compared to analysts’ expectations of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. As a group, sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CAO Theodore Alan Huizenga sold 967 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $40,710.70. Following the sale, the chief accounting officer now owns 50,265 shares in the company, valued at $2,116,156.50. This represents a 1.89 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Thomas Richard Kassberg sold 6,028 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $253,778.80. Following the completion of the sale, the executive vice president now owns 265,238 shares in the company, valued at approximately $11,166,519.80. This represents a 2.22 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 142,858 shares of company stock valued at $6,093,035. Corporate insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.